Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Safety and Pharmacokinetics of a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist, KBP-5074, in Hemodialysis and Non-Hemodialysis Patients with Severe Chronic Kidney Disease

Jeffrey Connaire, Mark Bush, Jon Ruckle, Fred Yang, Jinrong Liu, Xiaojuan Tan, Ping Wang, Tian Zhou, Min Zhang, Vincent Benn
doi: https://doi.org/10.1101/2020.05.12.20053314
Jeffrey Connaire
1DaVita Clinical Research, Minneapolis, Minnesota
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Bush
2Nuventra Pharma Sciences, Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon Ruckle
3Pacific Pharma Group, LLC, Tacoma, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Yang
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinrong Liu
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaojuan Tan
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ping Wang
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tian Zhou
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Zhang
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Benn
4KBP Biosciences Co., Ltd., Princeton, New Jersey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vince.benn@kbpbiosciences.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective KBP-5074 is a novel non-steroidal mineralocorticoid receptor antagonist for the potential treatment of hypertension. The purpose of this study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of 0.5 mg KBP-5074 in subjects with end stage renal disease on and not on hemodialysis.

Results Single doses of 0.5 mg KBP-5074 were generally well tolerated in both hemodialysis (N=6) and non-hemodialysis (N=5) subjects with severe renal impairment. Of the 11 subjects in the study, there was a single report of hyperkalemia in a hemodialysis subject on Day 14 that was not considered drug-related and was resolved in 2 days. Mean plasma KBP-5074 concentrations peaked at 6 and 4 hours in non-dialysis and dialysis subjects, respectively, and slowly declined through 312 hours postdose. Overall, the KBP-5074 exposures were significantly lower and had a shorter half-life in hemodialysis subjects compared with the non-hemodialysis subjects. However, hemodialysis had minimal direct impact on drug concentrations with negligible drug levels in the dialysate samples. Plasma aldosterone and serum potassium concentrations were generally comparable between non-hemodialysis and hemodialysis subjects, most likely to due to high variability in the hemodialysis subjects.

Conclusion The overall plasma exposure of KBP-5074 was statistically significantly lower in hemodialysis subjects compared to subjects with renal impairment not on hemodialysis.

Competing Interest Statement

VB, JL, XT, PW, TZ, MZ and FY are employees of KBP Biosciences. JC was the principal investigator and JR was the medical monitor of the study who received funding from KBP Biosciences for their involvement with the clinical conduct of the study. MB provided analytical support and was an employee of Wingate University School of Pharmacy at the time.

Clinical Trial

NCT02837237

Funding Statement

This study was fully supported by KBP Biosciences Co. Ltd.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Acknowledgements The study was funded by KBP BIOSCIENCES CO., LTD. We thank the participation of the local principal investigators and staff at the study sites. All authors reviewed drafts of the manuscript, approved the final version and agree to be accountable for the work. Medical writing support was provided by Guissou Dabiri, PhD of GD Scientific & Medical Writing, LLC and was funded by KBP Biosciences.

  • Conflict of Interest VB, JL, XT, PW, TZ, MZ and FY are employees of KBP Biosciences. JC was the principal investigator and JR was the medical monitor of the study who received funding from KBP Biosciences for their involvement with the clinical conduct of the study. MB provided analytical support and was an employee of Wingate University School of Pharmacy at the time.

  • Ethical Approval The study was approved on 17 May 2016 by IntegReview IRB, 3815 S. Capital of Texas Highway, Suite 320, Austin, TX 78704

Data Availability

All data resides in the trial master file maintained by KBP Biosciences Co. Ltd.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 15, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Safety and Pharmacokinetics of a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist, KBP-5074, in Hemodialysis and Non-Hemodialysis Patients with Severe Chronic Kidney Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Safety and Pharmacokinetics of a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist, KBP-5074, in Hemodialysis and Non-Hemodialysis Patients with Severe Chronic Kidney Disease
Jeffrey Connaire, Mark Bush, Jon Ruckle, Fred Yang, Jinrong Liu, Xiaojuan Tan, Ping Wang, Tian Zhou, Min Zhang, Vincent Benn
medRxiv 2020.05.12.20053314; doi: https://doi.org/10.1101/2020.05.12.20053314
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Safety and Pharmacokinetics of a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist, KBP-5074, in Hemodialysis and Non-Hemodialysis Patients with Severe Chronic Kidney Disease
Jeffrey Connaire, Mark Bush, Jon Ruckle, Fred Yang, Jinrong Liu, Xiaojuan Tan, Ping Wang, Tian Zhou, Min Zhang, Vincent Benn
medRxiv 2020.05.12.20053314; doi: https://doi.org/10.1101/2020.05.12.20053314

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Nephrology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (47)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (49)
  • Emergency Medicine (145)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4874)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (678)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (633)
  • Health Policy (322)
  • Health Systems and Quality Improvement (208)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5358)
  • Intensive Care and Critical Care Medicine (332)
  • Medical Education (94)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (690)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (127)
  • Occupational and Environmental Health (209)
  • Oncology (443)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (17)
  • Pathology (130)
  • Pediatrics (196)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (782)
  • Public and Global Health (1823)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)